Clinical trials of the world's first vaccine for COVID-19 has been completed by Russia's Sechenov University.

The COVID-19 vaccine study at Sechenov University has not completed human trials as the participants are to be monitored for six months.

The COVID-19 vaccine study at Sechenov University has not completed human trials as the participants are to be monitored for six months. The COVID-19 vaccine developed by the Gamalei Institute of Epidemiology and Microbiology has not completed the human trials.

The Russian Ministry of Health permitted the trials to be conducted at Sechenov University in Moscow. It began the clinical trials of the vaccine on June 18, 2020, with eighteen people. The second group of 20 healthy volunteers had received the vaccine on June 23. The vaccinated volunteers have to spend 28 days in the hospital for protection from other infectious diseases. They are to be monitored six months after discharge, for the vaccine to be regarded as safe for human consumption.

The World Health Organization has listed the vaccine, named Gam-COVID-Vac Lyo, as one of the candidate vaccines in clinical evaluation. Also, the Week reported in its piece on how the vaccine has not finished human trials.

The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.